0001213900-26-053368
SEC filingRevenue declined 28.7% to $18.7M amid U.S. sales pressures and Europe competition, with gross margin compressing to 10.7% from product mix shifts and inventory provisions, though operating losses narrowed 10.4% to -$9.5M and cash burn improved significantly.
Revenue of $18.7 million for Q3 FY2026 declined 28.7% from $26.2 million in the prior year quarter, reflecting reduced U.S. sales volume due to tighter credit terms imposed on customers and intensified competition in Europe. This sales contraction directly contributed to lower cost of revenue, though partially offset by additional inventory provisions accrued during the period, as noted in management's discussion.
Gross profit decreased 58.3% to $2.0 million, compressing the gross margin to 10.7% from higher prior-year levels. Management attributes this primarily to changes in product mix, with fewer higher-margin products sold during the three months ended March 31, 2026, compounded by the inventory provisions. These factors eroded profitability at the gross level, highlighting vulnerability to sales composition and inventory management challenges amid softer demand.
Operationally, Ispire Malaysia's full nicotine vapor manufacturing license, secured in March 2026, has generated a backlog of customer demand now that production can commence by end-June. Management believes production costs will match those in China and improve with scaling volume and capacity, enhanced by China's VAT rebate cancellation and stricter U.S. export controls—making Malaysia a viable alternative for nicotine vapor production and potential margin support in future periods.
Looking ahead, management anticipates continued operating cash flow improvements in 2026 driven by U.S. cost discipline, even as valuation allowance increases signal caution on near-term taxable income utilization from loss carryforwards.